Drugmakers received the first slice of FDA social media guidance in January, and now the FDA's mailbag is filling up with letters on First Amendment protections, "jurisdictional creep" and other topics from the likes of Pfizer and PhRMA.
Attention deficit hyperactivity disorder drugs like Ritalin have been on the FDA shortage list for a variety of reasons. Now add to that packaging problems which have led Novartis to recall nearly 22,000 bottles.
With growing demand for eye drugs in Asia, Novartis' Alcon unit wants to have the capacity to sell into that market. To be able to do that, the company has opened a new plant in Singapore to make a variety of its eye drugs.
Dr. John Porter, formerly the U.K. medical team lead for Pfizer, will become Novartis' medical affairs director for Northern Europe.
The COO of RNAi specialist Alnylam was critical of Big Pharma in the wake of Novartis' decision to slam the breaks on its RNAi research. The news made investors nervous about the future of the promising, but nascent technology and Alnylam stock price is down more than 20% in the last week.
The inability of Ranbaxy Laboratories to get its generic of heart drug Diovan to market for 18 months has been a boon for Novartis. Not so much for consumers.
Novartis is ticking off another 235 boxes on its job cuts list. The Swiss drugmaker plans to lay off 215 administrative and support staff in New Jersey by the end of June, and another 20 in similar positions elsewhere in the U.S., the Star-Ledger reports.
Just over a month into its search for "strategic options," ThromboGenics has rounded up a bevy of high-dollar offers that could value the company at as much as $1.3 billion, Bloomberg reports, courted by drugmakers who see promise in its underperforming eye drug.
Novartis is shuttering a large part of its once-ambitious RNAi research effort in Boston, FierceBiotech has learned.
Novartis is shuttering a large part of its once-ambitious RNAi research effort in Boston, FierceBiotech has learned. The pharma giant, which has extensive research operations in the Boston area, confirmed the decision, saying that the lingering problems associated with delivering these therapies tied to the small number of relevant targets they could shoot for drove the move.